High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds
The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
1. A compound having the following chemical structure:
or a stereoisomer thereof;
wherein F is selected from Structure FP-2, Structure FP-7, and Structure FI-4:
T is selected from Structure W-2 and Structure W-4
HA is selected from nothing, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, disulfuric acid, phosphoric acid, phosphorous acid, phosphonic acid, isonicotinic acid, acetic acid, lactic acid, salicylic acid, citric acid, tartaric acid, pantothenic acid, bitartaric acid, ascorbic acid, succinic acid, maleic acid, gentisinic acid, fumaric acid, gluconic acid, glucuronic acid, saccharic acid, formic acid, benzoic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzensulfonic acid, p-toluenesulfonic acid, and pamoic acid;
R is C 1 -C 12 alkyl;
R 1 is selected from H, C 1 -C 12 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocycloalkyl, C 1 -C 12 alkyloxyl, aryl, and heteroaryl residues;
R 5 is selected from H and C 1 -C 12 alkyl;
R 6 is selected from H, F, Cl, Br, I, C(═O)R 5 , 2-oxo-1-imidazolidinyl, phenyl, 5-indanyl, 2,3-dihydro-1H-inden-5-yl, 4-hydroxy-1,5-naphthyridin-3-yl, C 1 -C 12 alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 heterocycloalkyl, C 1 -C 12 alkyloxyl, C 3 -C 12 cycloalkyloxyl, aryl, and heteroaryl;
R 11 -R 13 are independently selected from C 1 -C 12 alkyl;
Y 1 -Y 4 and Y 31 are independently selected from OH, OC(═O)CH 3 , R 6 , CH 3 SO 2 , CH 3 SO 3 , NO 2 , CN, OCF 3 , CH 2 C(═O)NH 2 , C 1 -C 12 alkoxyl, C 1 -C 12 alkylamino, C 1 -C 12 alkyl halide, and C 1 -C 12 alkylcarbonyl;
L 1 is selected from nothing, O, and —N(H)—;
L 2 is selected from nothing, O, and —N(H)—; and
L 4 is C═O; wherein L 1 and L 2 cannot be nothing simultaneously.
2. A compound selected from:
6-(5-methyl-3-phenyl-2-isoxazoline-4-carboxamido)penicillinic acid 4-piperidineethyl ester.HA;
6-[3-(o-chlorophenyl)-5-methyl-4-isoxazolecarboxamido]penicillinic acid 3-piperidineethyl ester.HA;
6-[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxamido]penicillinic acid 1 piperidineethyl ester.HA;
D-α-[(imidazolidin-2-on-1-yl)carbonylamino]benzylpenicillin 2-pyrrolidinemethyl ester.HA;
6R-[2-[3-(methylsulfonyl)-2-oxo-1-imidazolidinecarboxamido]-2-phenylacetamido]penicillinic acid 1-pyrrolidineethyl ester.HA; and
[2S-(2alpha,3beta,5alpha)]-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide 1-piperidineethyl ester.HA;
wherein HA is selected from nothing, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, disulfuric acid, phosphoric acid, phosphorous acid, phosphonic acid, isonicotinic acid, acetic acid, lactic acid, salicylic acid, citric acid, tartaric acid, pantothenic acid, bitartaric acid, ascorbic acid, succinic acid, maleic acid, gentisinic acid, fumaric acid, gluconic acid, glucuronic acid, saccharic acid, formic acid, benzoic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzensulfonic acid, p-toluenesulfonic acid, and pamoic acid.
3. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition according to claim 3 , wherein the pharmaceutically acceptable carrier is selected from alcohol, acetone, ester, water, and aqueous solution.
5. A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable carrier.
6. The pharmaceutical composition according to claim 5 , wherein the pharmaceutically acceptable carrier is selected from alcohol, acetone, ester, water, and aqueous solution.
7. The compound of claim 1 , wherein F is Structure FP-2.
8. The compound of claim 1 , wherein F is Structure FP-7.
9. The compound of claim 1 , wherein F is Structure FI-4.
10. The compound of claim 1 , wherein T is Structure W-2.
11. The compound of claim 1 , wherein T is Structure W-4.
12. The compound of claim 2 , wherein the compound is 6-(5-methyl-3-phenyl-2-isoxazoline-4-carboxamido)penicillinic acid 4-piperidineethyl ester.HCl.
13. The compound of claim 2 , wherein the compound is 6-[3-(o-chlorophenyl)-5-methyl-4-isoxazolecarboxamido]penicillinic acid 3-piperidineethyl ester.HCl.
14. The compound of claim 2 , wherein the compound is 6-[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxamido]penicillinic acid 1-piperidineethyl ester.HCl.
15. The compound of claim 2 , wherein the compound is D-α-[(imidazolidin-2-on-1-yl)carbonylamino]benzylpenicillin 2-pyrrolidinemethyl ester.HCl.
16. The compound of claim 2 , wherein the compound is 6R-[2-[3-(methylsulfonyl)-2-oxo-1-imidazolidinecarboxamido]-2-phenylacetamido]penicillinic acid 1-pyrrolidineethyl ester.HCl.
17. The compound of claim 2 , wherein the compound is [2S-(2alpha,3beta,5alpha)]-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide 1-piperidineethyl ester HCl.